biotech / news / / Medical Xpress
AstraZeneca's Enhertu (fam-trastuzumab deruxtecan-nxki) approved for both neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer.
FDA approved AstraZeneca's Enhertu for neoadjuvant and adjuvant treatment of HER2-positive early breast cancer.
KEY POINTS
- In DESTINY-Breast11, Enhertu followed by THP yielded a 67.3% pathologic complete response versus 56.3% with standard care.
- DESTINY-Breast05 results showed Enhertu reduced risk of invasive recurrence or death by 53% versus T-DM1.
- At three years, 92.4% of Enhertu-treated patients were disease-free compared to 83.7% for T-DM1.
COMPANIES
Summarized by Newsio from Medical Xpress. How we summarize →